Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HENRY DAVID MITCHESON

Allopathic & Osteopathic Physicians Urology

NPI
1609878065
CMS profile
26956
Location
WATERTOWN, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$6,808.44

5 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $5,462.50 1
Travel and Lodging $1,345.94 4

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Eli Lilly and Company $6,808.44 5

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HENRY DAVID MITCHESON

NPI 1609878065 · CMS profile ID 26956

Allopathic & Osteopathic Physicians / Urology

WATERTOWN, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1609878065?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HENRY DAVID MITCHESON, NPI 1609878065, CMS profile ID 26956. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1609878065?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). HENRY DAVID MITCHESON, NPI 1609878065, CMS profile ID 26956. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1609878065?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
HENRY DAVID MITCHESON, NPI 1609878065, CMS profile ID 26956, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1609878065?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

5 matching records · $6,808.44 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 5 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–5 of 5.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Eli Lilly and Company $5,462.5006/13/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1186577922 CMS
Eli Lilly and Company $124.7705/01/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186564570 CMS
Eli Lilly and Company $83.0005/01/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186621342 CMS
Eli Lilly and Company $209.0005/01/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186633199 CMS
Eli Lilly and Company $929.1705/01/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186648137 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $33.06 2
PY2020 $27.36 2
PY2021 $141.90 3
PY2023 $820.37 6
PY2025 $6,808.44 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $79,797.01 17
PY2024 Principal investigator $298,781.41 38
PY2023 Principal investigator $246,483.30 35
PY2022 Principal investigator $371,578.62 51
PY2021 Principal investigator $151,239.97 33
PY2020 Principal investigator $214,565.33 26
PY2019 Recipient $1,155.55 5
PY2019 Principal investigator $196,628.49 22

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

33 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan, Inc. $133.32 12/31/2021 Non-covered Recipient Entity
BAY STATE CLINICAL TRIALS INCORPORATED
A PHASE IV, MULTI-CENTER, OPEN-LABEL, SINGLE-ARM 24-HOUR AMBULATORY BLOOD PRESSURE MONITORING (ABPM) STUDY OF 16 WEEKS TREATMENT WITH ANDRODERM IN HYPOGONADAL MEN No dispute reported 06/30/2026 789003567
Principal investigator 1 UROVANT SCIENCES INC $29.15 12/31/2021 Non-covered Recipient Entity
BAY STATE CLINICAL TRIALS INC
A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) No dispute reported 06/30/2026 837698529
Principal investigator 1 UROVANT SCIENCES INC $3,678.37 12/23/2021 Non-covered Recipient Entity
INTERSPOND LLC
A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) No dispute reported 06/30/2026 837699295
Principal investigator 1 UROVANT SCIENCES INC $377.10 12/22/2021 Non-covered Recipient Entity
BAY STATE CLINICAL TRIALS INC
An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of URO-902 in Subjects With Overactive Bladder and Urge Urinary Incontinence No dispute reported 06/30/2026 837698507
Principal investigator 1 UROVANT SCIENCES INC $48,264.78 12/20/2021 Non-covered Recipient Entity
INTERSPOND LLC
A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) No dispute reported 06/30/2026 837699303
Principal investigator 1 UROVANT SCIENCES INC $25,163.85 12/16/2021 Non-covered Recipient Entity
INTERSPOND LLC
A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) No dispute reported 06/30/2026 837699299
Principal investigator 1 UROVANT SCIENCES INC $257.00 12/15/2021 Non-covered Recipient Entity
BAY STATE CLINICAL TRIALS INC
An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of URO-902 in Subjects With Overactive Bladder and Urge Urinary Incontinence No dispute reported 06/30/2026 837698525
Principal investigator 1 GlaxoSmithKline, LLC. $583.50 12/09/2021 Non-covered Recipient Entity
BAY STATE CLINICAL TRIALS INC
A PHASE 3 STUDY TO COMPARE THE EFFICACY AND SAFETY OF GEPOTIDACIN WITH No dispute reported 06/30/2026 860870381
Principal investigator 1 UROVANT SCIENCES INC $600.00 11/30/2021 Non-covered Recipient Entity
INTERSPOND LLC
A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) No dispute reported 06/30/2026 837699213
Principal investigator 1 UROVANT SCIENCES INC $1,131.30 11/26/2021 Non-covered Recipient Entity
BAY STATE CLINICAL TRIALS INC
An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of URO-902 in Subjects With Overactive Bladder and Urge Urinary Incontinence No dispute reported 06/30/2026 837698499
Principal investigator 1 UROVANT SCIENCES INC $3,016.80 11/24/2021 Non-covered Recipient Entity
BAY STATE CLINICAL TRIALS INC
An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of URO-902 in Subjects With Overactive Bladder and Urge Urinary Incontinence No dispute reported 06/30/2026 837698491
Principal investigator 1 GlaxoSmithKline, LLC. $1,454.50 11/19/2021 Non-covered Recipient Entity
BAY STATE CLINICAL TRIALS INC
A PHASE 3 STUDY TO COMPARE THE EFFICACY AND SAFETY OF GEPOTIDACIN WITH No dispute reported 06/30/2026 860868675
Principal investigator 1 UROVANT SCIENCES INC $3,024.00 11/16/2021 Non-covered Recipient Entity
INTERSPOND LLC
A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) No dispute reported 06/30/2026 837699221
Principal investigator 1 UROVANT SCIENCES INC $6,064.16 11/10/2021 Non-covered Recipient Entity
INTERSPOND LLC
A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) No dispute reported 06/30/2026 837699205
Principal investigator 1 UROVANT SCIENCES INC $2,551.90 11/08/2021 Non-covered Recipient Entity
INTERSPOND LLC
A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) No dispute reported 06/30/2026 837699209
Principal investigator 1 UROVANT SCIENCES INC $896.44 11/08/2021 Non-covered Recipient Entity
INTERSPOND LLC
A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) No dispute reported 06/30/2026 837699217
Principal investigator 1 Allergan, Inc. $7,588.00 10/18/2021 Non-covered Recipient Entity
BAY STATE CLINICAL TRIALS
Androderm 24-Hr ABPM No dispute reported 06/30/2026 789003565
Principal investigator 1 UROVANT SCIENCES INC $66.80 10/12/2021 Non-covered Recipient Entity
BAY STATE CLINICAL TRIALS INC
A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) No dispute reported 06/30/2026 837698417
Principal investigator 1 GlaxoSmithKline, LLC. $156.00 08/28/2021 Non-covered Recipient Entity
BAY STATE CLINICAL TRIALS INC
A PHASE 3 STUDY TO COMPARE THE EFFICACY AND SAFETY OF GEPOTIDACIN WITH No dispute reported 06/30/2026 860870383
Principal investigator 1 GlaxoSmithKline, LLC. $1,300.00 08/28/2021 Non-covered Recipient Entity
BAY STATE CLINICAL TRIALS INC
A PHASE 3 STUDY TO COMPARE THE EFFICACY AND SAFETY OF GEPOTIDACIN WITH No dispute reported 06/30/2026 860872157
Principal investigator 1 Allergan, Inc. $1,500.00 08/12/2021 Non-covered Recipient Entity
BAY STATE CLINICAL TRIALS
Androderm 24-Hr ABPM No dispute reported 06/30/2026 789003561
Principal investigator 1 Allergan, Inc. $1,000.00 08/12/2021 Non-covered Recipient Entity
BAY STATE CLINICAL TRIALS
Androderm 24-Hr ABPM No dispute reported 06/30/2026 789003563
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 05/24/2021 Non-covered Recipient Entity
BAY STATE CLINICAL TRIALS INC
A PHASE 3 STUDY TO COMPARE THE EFFICACY AND SAFETY OF GEPOTIDACIN WITH No dispute reported 06/30/2026 860868731
Principal investigator 1 Allergan, Inc. $2,199.25 05/13/2021 Non-covered Recipient Entity
BAY STATE CLINICAL TRIALS
Androderm 24-Hr ABPM No dispute reported 06/30/2026 789003559
Principal investigator 1 Allergan, Inc. $3,850.00 04/23/2021 Non-covered Recipient Entity
BAY STATE CLINICAL TRIALS
Androderm 24-Hr ABPM No dispute reported 06/30/2026 789003557
Principal investigator 1 Allergan, Inc. $855.00 04/13/2021 Non-covered Recipient Entity
BAY STATE CLINICAL TRIALS
Androderm 24-Hr ABPM No dispute reported 06/30/2026 789003555
Principal investigator 1 Allergan, Inc. $3,766.75 03/16/2021 Non-covered Recipient Entity
BAY STATE CLINICAL TRIALS
Androderm 24-Hr ABPM No dispute reported 06/30/2026 789003553
Principal investigator 1 Janssen Research & Development, LLC $2,500.00 03/11/2021 Non-covered Recipient Entity
BAY STATE CLINICAL TRIALS INC
A prospective Multi Center open label study of trospium delivered intravesically by TAR3025018 to subjects with idiopathic overactive bladder iOAB and urinary incontinence. No dispute reported 06/30/2026 787624407
Principal investigator 1 Allergan, Inc. $3,850.00 03/01/2021 Non-covered Recipient Entity
BAY STATE CLINICAL TRIALS
Androderm 24-Hr ABPM No dispute reported 06/30/2026 789003551
Principal investigator 1 Allergan, Inc. $17,760.25 02/17/2021 Non-covered Recipient Entity
BAY STATE CLINICAL TRIALS
Androderm 24-Hr ABPM No dispute reported 06/30/2026 789003549
Principal investigator 1 Allergan, Inc. $5,191.75 01/15/2021 Non-covered Recipient Entity
BAY STATE CLINICAL TRIALS
Androderm 24-Hr ABPM No dispute reported 06/30/2026 789003547
Principal investigator 1 Allergan, Inc. $880.00 01/05/2021 Non-covered Recipient Entity
BAY STATE CLINICAL TRIALS
Androderm 24-Hr ABPM No dispute reported 06/30/2026 789003543
Principal investigator 1 Allergan, Inc. $1,050.00 01/05/2021 Non-covered Recipient Entity
BAY STATE CLINICAL TRIALS
Androderm 24-Hr ABPM No dispute reported 06/30/2026 789003545